Clinical trial
Combination Daclizumab/Denileukin Diftitox to Treat Uveitis
NCT00326508 · National Eye Institute (NEI), NIH · Completed
Key facts
| NCT number | NCT00326508 |
|---|---|
| Title | Combination Daclizumab/Denileukin Diftitox to Treat Uveitis |
| Official title | Combination Daclizumab/Denileukin Diftitox (Ontak) Therapy for the Induction of Immune Tolerance in Non-infectious Intermediate and Posterior Uveitis |
| Lead sponsor | National Eye Institute (NEI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-infectious Intermediate and Posterior Uveitis |
| Intervention type | Drug |
| Interventions | Daclizumab |
| Enrollment | 5 |
| Start date | May 11, 2006 |
| Completion | Dec 20, 2006 |
| First posted | May 17, 2006 |
| Last update posted | Jul 2, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: